Work

Strategic Studies in Radiopharmaceuticals: an Overview of Brazilian and Global Health Technologies in Oncological Therapy

Year: 2026
Type: article
Abstract: Radiopharmaceuticals are essential for the diagnosis and treatment of cancer, but their supply has been a long-standing problem in Brazil. Constitutional Amendment No. 118 (2022), which ended the state monopoly on the production of medical radioisotopes, opened a new scenario for this market. This study aimed to evaluate the Brazilian and global overview of radiopharmaceuticals used in oncology, in order to generate technological information for decision-making in the Brazilian Unified Health System (SUS). The methodology comprised three stages: (i) a search for radiopharmaceuticals with active registration in the database of the National Health Surveillance Agency (ANVISA), classified under ATC codes V09 and V10; (ii) a survey of radiotherapy-related procedures in the SUS, using DATASUS, SIGTAP and the Painel Oncologia Brasil; and (iii) a search of the Cortellis Drug Discovery Intelligence (CDDI) database, which retrieved 5,644 pharmaceuticals and biologicals. The results show a diverse set of registered products, with fludeoxyglucose 18F (18F-FDG) holding the largest number of registrations, by several companies, and describe the regulatory framework applicable to these products. Globally, few radiopharmaceuticals reach the market compared with the number in preclinical and clinical development; gallium (759 records) and technetium (536) were the elements most often found in complexes, and fluorine was the most frequent in radiolabeled products. The study provides initial strategic information for researchers, managers and decision-makers and may contribute to strengthening nuclear medicine in the SUS.
Language: English
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7236125518
FWCI:
Cites: 3
Cited by:
Related to: 10